Cargando…

Multiple SARS-CoV-2 Variants Exhibit Variable Target Cell Infectivity and Ability to Evade Antibody Neutralization

The continuous emergence of SARS-coronavirus 2 (SARS-CoV-2) variants, especially the variants of concern (VOC), exacerbated the impact of the coronavirus disease 2019 (COVID-19) pandemic. As the key of viral entry into host cells, the spike (S) protein is the major target of therapeutic monoclonal a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, Haijun, Gao, Long, Wu, Zhao, Meng, Fang, Zhao, Xin, Shao, Yun, Hou, Guocun, Du, Xiaohong, Qin, F. Xiao-Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966392/ https://www.ncbi.nlm.nih.gov/pubmed/35371108 http://dx.doi.org/10.3389/fimmu.2022.836232

Ejemplares similares

The great escape? SARS-CoV-2 variants evading neutralizing responses
por: Prévost, Jérémie, et al.
Publicado: (2021)

A humanized anti-human adenovirus 55 monoclonal antibody with good neutralization ability
por: Chen, Lei, et al.
Publicado: (2023)

Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants
por: Shrestha, Lok Bahadur, et al.
Publicado: (2021)

A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants
por: Shan, Sisi, et al.
Publicado: (2021)

Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern
por: Favorskaya, Irina A., et al.
Publicado: (2022)

Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization
por: Zhang, Li, et al.
Publicado: (2021)

SARS-CoV-2 variant evades antibodies whilst maintaining fitness
por: Flemming, Alexandra
Publicado: (2021)

SARS-CoV-2 Omicron Variants Reduce Antibody Neutralization and Acquire Usage of Mouse ACE2
por: Wang, Ruoke, et al.
Publicado: (2022)

WNT Signaling in Tumors: The Way to Evade Drugs and Immunity
por: Martin-Orozco, Elena, et al.
Publicado: (2019)

Avidity engineering of human heavy-chain-only antibodies mitigates neutralization resistance of SARS-CoV-2 variants
por: Du, Wenjuan, et al.
Publicado: (2023)

Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies
por: Tada, Takuya, et al.
Publicado: (2022)

SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum, but evades most convalescent serum and therapeutic antibodies
por: Lusvarghi, Sabrina, et al.
Publicado: (2022)

Sensitivity of SARS-CoV-2 Variants to Neutralization by Convalescent Sera and a VH3-30 Monoclonal Antibody
por: Yue, Shuai, et al.
Publicado: (2021)

Protein re-surfacing of E. coli L-Asparaginase to evade pre-existing anti-drug antibodies and hypersensitivity responses
por: Bootwala, Ali, et al.
Publicado: (2022)

Characterization of RBD-specific cross-neutralizing antibodies responses against SARS-CoV-2 variants from COVID-19 convalescents
por: Wang, Zheng, et al.
Publicado: (2023)

Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern
por: Deshpande, Ashlesha, et al.
Publicado: (2021)

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
por: Weisblum, Yiska, et al.
Publicado: (2020)

The Effects of Framework Mutations at the Variable Domain Interface on Antibody Affinity Maturation in an HIV-1 Broadly Neutralizing Antibody Lineage
por: Zhou, Jeffrey O., et al.
Publicado: (2020)

Poly-Gamma-Glutamic Acid (γ-PGA)-Based Encapsulation of Adenovirus to Evade Neutralizing Antibodies
por: Khalil, Ibrahim R., et al.
Publicado: (2018)

Bat adeno-associated viruses as gene therapy vectors with the potential to evade human neutralizing antibodies
por: Li, Ya, et al.
Publicado: (2019)

MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants
por: Lee, Sua, et al.
Publicado: (2021)

Is It Possible to Intervene in the Capacity of Trypanosoma cruzi to Elicit and Evade the Complement System?
por: Ramírez-Toloza, Galia, et al.
Publicado: (2021)

The Ability of Porcine Reproductive and Respiratory Syndrome Virus Isolates to Induce Broadly Reactive Neutralizing Antibodies Correlates With In Vivo Protection
por: Martínez-Lobo, Francisco Javier, et al.
Publicado: (2021)

Corrigendum: The Effects of Framework Mutations at the Variable Domain Interface on Antibody Affinity Maturation in an HIV-1 Broadly Neutralizing Antibody Lineage
por: Zhou, Jeffrey O., et al.
Publicado: (2020)

SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccination
por: Arora, Prerna, et al.
Publicado: (2022)

Detection and Neutralization of SARS-CoV-2 Using Non-conventional Variable Lymphocyte Receptor Antibodies of the Evolutionarily Distant Sea Lamprey
por: Leung, Leslie Y. T., et al.
Publicado: (2021)

Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination
por: Hernández-Luis, Pablo, et al.
Publicado: (2022)

Pan-neutralizing, germline-encoded antibodies against SARS-CoV-2: Addressing the long-term problem of escape variants
por: Lunderberg, Justin Mark, et al.
Publicado: (2022)

A flow cytometry-based neutralization assay for simultaneous evaluation of blocking antibodies against SARS-CoV-2 variants
por: Egia-Mendikute, Leire, et al.
Publicado: (2022)

Simultaneous measurement of multiple variant-specific SARS-CoV-2 neutralizing antibodies with a multiplexed flow cytometric assay
por: Liu, Hong, et al.
Publicado: (2022)

Leishmania infantum and Leishmania braziliensis: Differences and Similarities to Evade the Innate Immune System
por: Falcão, Sarah de Athayde Couto, et al.
Publicado: (2016)

Edwardsiella tarda Tunes Tricarboxylic Acid Cycle to Evade Complement-Mediated Killing
por: Cheng, Zhi-xue, et al.
Publicado: (2017)

Engineered cord blood megakaryocytes evade killing by allogeneic T-cells for refractory thrombocytopenia
por: Kumar, Bijender, et al.
Publicado: (2022)

Neutralizing Ability of a Single Domain VNAR Antibody: In Vitro Neutralization of SARS-CoV-2 Variants of Concern
por: Valdovino-Navarro, Blanca J., et al.
Publicado: (2022)

Hexamerization of Anti-SARS CoV IgG1 Antibodies Improves Neutralization Capacity
por: Pande, Kalyan, et al.
Publicado: (2022)

Optimized AAV rh.10 Vectors That Partially Evade Neutralizing Antibodies during Hepatic Gene Transfer
por: Selot, Ruchita, et al.
Publicado: (2017)

Combinations of Single Chain Variable Fragments From HIV Broadly Neutralizing Antibodies Demonstrate High Potency and Breadth
por: van Dorsten, Rebecca T., et al.
Publicado: (2021)

Cross-reactive neutralizing human monoclonal antibodies mapping to variable antigenic sites on the norovirus major capsid protein
por: Ford-Siltz, Lauren A., et al.
Publicado: (2022)

Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants
por: Lin, Wei-Shuo, et al.
Publicado: (2021)

A novel bispecific antibody dual-targeting approach for enhanced neutralization against fast-evolving SARS-CoV-2 variants
por: Kim, Ji Woong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v2einvch0j4r0cdgeq7uktehdb